UDP‐Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo

The response to statins shows large interpatient variability. Atorvastatin δ‐lactone is pharmacologically inactive but has been associated with toxicity. We investigated the role of UDP‐glucuronosyltransferases (UGTs) in atorvastatin lactonization. In human liver microsomes, lactonization was correlated with UGT1A3 (rs = 0.61, P < 0.0001) but not with UGT1A1. Surprisingly, lactone formation was significantly higher in carriers of UGT1A1*28, an allele that is associated with lower UGT1A1 expression. We show that this inverse correlation is due to extensive linkage disequilibrium in the UGT1A locus and that several UGT1A3 haplotypes are associated with strong increases in UGT1A3 expression in vitro. Analyses of the pharmacokinetic parameters of atorvastatin and metabolites in genotyped volunteers confirmed that there is an increase in atorvastatin lactonization in carriers of UGT1A3*2 in vivo. The potential of UGT genotyping to identify patients who are at increased risk for failure of therapy and/or adverse effects of statins warrants further investigation.

[1]  P. Neuvonen,et al.  ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.

[2]  S. Amin,et al.  Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases , 2007, Drug Metabolism and Disposition.

[3]  S. Yamada,et al.  Hepatic UDP-Glucuronosyltransferases Responsible for Glucuronidation of Thyroxine in Humans , 2008, Drug Metabolism and Disposition.

[4]  R. Subramanian,et al.  ACYL-COENZYME A FORMATION OF SIMVASTATIN IN MOUSE LIVER PREPARATIONS , 2006, Drug Metabolism and Disposition.

[5]  S. Zeng,et al.  Genetic Variants of Human UGT1A3: Functional Characterization and Frequency Distribution in a Chinese Han Population , 2006, Drug Metabolism and Disposition.

[6]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[7]  C. Guillemette,et al.  A pharmacogenomics study of the human estrogen glucuronosyltransferase UGT1A3 , 2007, Pharmacogenetics and genomics.

[8]  Matthew A Silva,et al.  Statin-related adverse events: a meta-analysis. , 2006, Clinical therapeutics.

[9]  F. Hobbs,et al.  Achievement of English National Service Framework lipid‐lowering goals: pooled data from recent comparative treatment trials of statins at starting doses , 2005, International journal of clinical practice.

[10]  F. Schmidt.  Meta-Analysis , 2008 .

[11]  Mikko Niemi,et al.  SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.

[12]  Michael Z. Man,et al.  Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. , 2007, British journal of clinical pharmacology.

[13]  R. Remmel,et al.  Variation in glucuronidation of lamotrigine in human liver microsomes , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  D. Hum,et al.  N-glycosylation and residue 96 are involved in the functional properties of UDP-glucuronosyltransferase enzymes. , 2000, Biochemistry.

[15]  B. Arison,et al.  In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[16]  P. Kollman,et al.  Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[17]  Ikumi Chisaki,et al.  Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. , 2008, Life sciences.

[18]  T. Sakaeda,et al.  Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  O. Barbier,et al.  Lipid-activated transcription factors control bile acid glucuronidation , 2009, Molecular and Cellular Biochemistry.

[20]  M. Schwab,et al.  Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. , 2009, Pharmacogenomics.

[21]  A. Åsberg,et al.  Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  Albert S. Kearney,et al.  The Interconversion Kinetics, Equilibrium, and Solubilities of the Lactone and Hydroxyacid Forms of the HMG-CoA Reductase Inhibitor, CI-981 , 1993, Pharmaceutical Research.

[23]  W. Humphreys,et al.  Characterization of the UDP Glucuronosyltransferase Activity of Human Liver Microsomes Genotyped for the UGT1A1*28 Polymorphism , 2007, Drug Metabolism and Disposition.

[24]  Alicja R Rudnicka,et al.  Statin safety: a systematic review. , 2006, The American journal of cardiology.

[25]  A. Åsberg,et al.  Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several‐fold in patients with atorvastatin‐induced myopathy , 2006, Clinical pharmacology and therapeutics.

[26]  C. Guillemette,et al.  Analysis of inherited genetic variations at the UGT1 locus in the French‐Canadian population , 2009, Human mutation.

[27]  B. Burchell,et al.  Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome , 1996, The Lancet.

[28]  Masaki Ito,et al.  Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity , 2004, Journal of Human Genetics.

[29]  C Watson,et al.  Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[30]  R. Krauss,et al.  Pharmacogenomics of statin response , 2007, Current opinion in lipidology.

[31]  Yuichi Sugiyama,et al.  Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.

[32]  K. Bock,et al.  Coordinate Regulation of Drug Metabolism by Xenobiotic Nuclear Receptors: UGTs Acting Together with CYPs and Glucuronide Transporters , 2004, Drug metabolism reviews.

[33]  P. Neuvonen,et al.  Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance , 2006, Clinical pharmacology and therapeutics.

[34]  P. Neuvonen,et al.  ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin , 2008, Clinical pharmacology and therapeutics.

[35]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[36]  J. Harraway,et al.  Use of fully denaturing HPLC for UGT1A1 genotyping in Gilbert syndrome. , 2005, Clinical chemistry.

[37]  P. O'dwyer,et al.  Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  B. Ma,et al.  Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[39]  M. Hirata,et al.  The genetic determinants of atorvastatin response. , 2007, Current opinion in molecular therapeutics.

[40]  Chongwoo Yu,et al.  Atorvastatin Glucuronidation Is Minimally and Nonselectively Inhibited by the Fibrates Gemfibrozil, Fenofibrate, and Fenofibric Acid , 2007, Drug Metabolism and Disposition.

[41]  C. Guillemette,et al.  Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. , 2005, Pharmacogenetics and genomics.

[42]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.

[43]  U. Hofmann,et al.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.